XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Commercial Services and Loan Agreements with Eversana - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Feb. 01, 2022
Jan. 21, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jan. 31, 2020
Commercial Services And Loan Agreements [Line Items]              
Selling, general and administrative     $ 2,315,175 $ 2,142,149 $ 4,720,251 $ 4,480,443  
Eversana Agreement [Member]              
Commercial Services And Loan Agreements [Line Items]              
Unreimbursed commercialization cost     38,400,000   $ 38,400,000    
Agreement expiration date Dec. 31, 2026            
Agreement term         On February 1, 2022, the Eversana Agreement was amended (the “Amended Eversana Agreement”) to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms.    
Selling, general and administrative     $ 368,000 $ 192,100 $ 716,000 $ 268,000  
Eversana Agreement [Member] | Revolving Credit Facility [Member]              
Commercial Services And Loan Agreements [Line Items]              
Line of credit   $ 5,000,000          
Line of credit facility, Interest rate   10.00%          
Borrowings             $ 5,000,000
Eversana Agreement [Member] | Gimoti [Member] | Minimum [Member]              
Commercial Services And Loan Agreements [Line Items]              
Percentage Of Product Profits   80.00%